0.25 CME/CE Credit
COPD Treatment for Primary Care ProvidersPart 2: Lung Health Updates for Primary Care Providers: Conversations with NHLBI
“Lung Health Updates for Primary Care Providers: Conversations with NHLBI” is a series of CME podcast episodes produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode on COPD treatment for primary care providers, we are joined by Dr. Mihaela Stefan, a Program Officer with NHLBI’s Division of Lung Diseases, and Dr. MeiLan Han, Professor of Medicine and Chief of the Division of Pulmonary and Critical Care at the University of Michigan. We’ll be discussing the range of treatments for patients diagnosed with COPD using spirometry, including lifestyle interventions, pulmonary rehabilitation, medications, and non-medication COPD treatments.
Already listened on another platform?
- Review lifestyle changes that primary care providers can recommend to improve the quality of life for all patients with COPD
- Discuss the role of pulmonary rehab in COPD
- Review classes of medication used for COPD treatment
- Discuss additional non-pharmacologic COPD treatments for patients with severe cases of COPD, including oxygen supplementation, surgery, and palliative approaches
Mihaela Stefan, MD, PhD
Program Officer with National Heart, Lung, and Blood Institute, National Institutes of HealthLearn More
MeiLan Han, MD
Professor of Medicine and Chief of the Division of Pulmonary and Critical Care at the University of MichiganLearn More
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Mihaela Stefan, MD: No relevant financial relationships
MeiLan Han, MD: Advisory Board: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, Regeneron; Research: Astrazeneca, Boehringer Ingelheim, Gala Therapeutics, Biodesix, the COPD Foundation and the American Lung Association; Stock Options from Meissa Vaccines and Altesa Biopharma; Consultant: GlaxoSmithKline.
Charles Vega, MD: Consultant, GlaxoSmithKline.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and National Heart, Lung and Blood Institute’s Breath Better Network. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supporters and Partners
Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.